TADCLOT- a Double Blind Randomized Controlled Trial
Status:
COMPLETED
Trial end date:
2025-02-20
Target enrollment:
Participant gender:
Summary
Compare the safety and efficacy of a twice-daily Clopidogrel regimen vs. Ticagrelor in reducing major adverse events in patients undergoing primary PCI in a double-blind randomized controlled trial.
Phase:
PHASE3
Details
Lead Sponsor:
National Institute of Cardiovascular Diseases, Pakistan